Asia-Pacific Fintech Market to Hit $348.1 Bn by 2031, as Real-Time Payments, Super-Apps and Digital Banking Gain Ground, Says Mordor Intelligence

Asia-Pacific Fintech Market Size and Share | Mordor Intelligence

Mordor Intelligence has published a new report on the Asia-Pacific fintech market offering a comprehensive analysis of trends, growth drivers, and future projections.

Hyderabad, India, October 31, 2026: According to Mordor Intelligence, The Asia-Pacific Fintech Market is estimated at USD 167.71 billion in 2026 and is projected to reach USD 348.1 billion by 2031, expanding at a CAGR of 15.76% during the forecast period. According to Mordor Intelligence, growth is supported by the wider adoption of real-time payment infrastructure, mobile-first financial services, digital identity programs, and digital banking across the region.

The Asia-Pacific fintech industry serves consumers and businesses through digital payments, lending, investments, insurance technology, and neobanking services. Increasing smartphone usage, expanding digital commerce, and government initiatives supporting cashless transactions are creating more opportunities for fintech providers. Financial institutions are also working with fintech companies to deliver digital services and reach customer groups that have traditionally had limited access to formal financial products.

The Asia-Pacific fintech market size is supported by the growing use of mobile applications and digital financial platforms. While market conditions vary across countries, the region has a broad mix of mature financial systems and developing economies where digital services are expanding rapidly. Regulatory differences, cybersecurity requirements, and data-localization rules remain important factors for companies operating across multiple markets.

Asia-Pacific Fintech Market Growth Drivers

Real-Time Payment Rails Support Digital Transactions

The expansion of real-time payment infrastructure is one of the major Asia-Pacific Fintech Market Trends. Payment networks such as India's UPI, Singapore's PayNow, and Thailand's PromptPay are making instant transfers increasingly common for consumers and businesses. Cross-border connectivity between payment systems is also creating opportunities for remittances, merchant payments, and business transactions.

Real-time payment rails allow fintech providers to build services around established payment infrastructure through application programming interfaces. QR-based payments are also supporting adoption among small merchants because they can accept digital transactions without relying heavily on traditional payment terminals.

Digital Identity Programs Expand Financial Inclusion

Government-backed digital identity and electronic know-your-customer systems are helping financial service providers simplify customer onboarding. These systems allow banks and fintech companies to verify customers more efficiently and support access to banking, insurance, investment, and payment products.

Financial inclusion remains an important opportunity across emerging Asia-Pacific markets. Digital platforms can reach consumers in rural areas and small businesses that may have limited access to traditional banking infrastructure. As identity systems and digital account access improve, fintech providers can expand their customer base through mobile-led financial services.

Super-Apps and Embedded Finance Increase Usage

Super-app ecosystems are combining payments and other financial services with commerce, mobility, food delivery, and other everyday activities. Companies such as Ant Group, Tencent, Grab, and GoTo have developed platforms where users can access several services through a single digital environment.

Embedded finance is also gaining traction among businesses. E-commerce platforms and supply chain systems are incorporating payments, lending, working-capital finance, and other services into existing workflows. This approach gives fintech companies additional distribution channels while allowing businesses to access financial products within platforms they already use.

Neobanking and Digital Financial Services Expand

Neobanking is gaining attention as digital-first financial providers expand their presence across the region. Digital banks can offer savings, payments, lending, and other financial products through online channels, supported by technology-led operating models.

Digital investment and insurtech services are also creating new opportunities. Wealth management platforms can provide investment products through mobile interfaces, while insurance technology providers can distribute coverage through digital commerce and mobility platforms. These services are helping broaden the range of financial products available through digital channels.

Access This Report in Japanese: https://www.mordorintelligence.com/ja/industry-reports/asia-pacific-fintech-market?utm_source=abnewswire

Asia-Pacific Fintech Market Segmentation

By Service Proposition

• Digital Payments

• Digital Lending and Financing

• Digital Investments

• Insurtech

• Neobanking

By End-User

• Retail

• Businesses

By User Interface

• Mobile Applications

• Web / Browser

• POS / IoT Devices

By Geography

• India

• China

• Japan

• Australia

• South Korea

• South-East Asia

• Singapore

• Malaysia

• Thailand

• Indonesia

• Vietnam

• Philippines

• Rest of Asia-Pacific

Explore Our Full Library of Financial Services and Investment Intelligence Research Reports: https://www.mordorintelligence.com/market-analysis/financial-services-and-investment-intelligence?utm_source=abnewswire

Asia-Pacific Fintech Market Geography Analysis

China remains a major fintech market, supported by established digital payment ecosystems and extensive consumer adoption. India is expected to record the fastest growth among the major regional markets, supported by real-time payments, digital identity infrastructure, financial inclusion initiatives, and digital lending frameworks.

Southeast Asia represents another important growth area. Singapore serves as a major financial technology hub, supported by its regulatory environment and cross-border payment initiatives. Indonesia offers a large domestic customer base and continued demand for financial inclusion services, while the Philippines benefits from demand for digital money transfer and remittance solutions.

Australia and Japan have more mature financial systems and established regulatory environments. These markets provide opportunities for digital banking, wealth management, payments, and other technology-based financial services. South Korea also has a developed digital financial ecosystem supported by high technology adoption and established digital payment usage.

Asia-Pacific Fintech Market Key Players

The Asia-Pacific Fintech Market includes global fintech companies, regional platforms, digital banks, payment providers, and specialized financial technology firms. Major companies covered by Mordor Intelligence include Ant Group, Tencent Holdings, Paytm, Grab Financial Group, Kakao Pay, GCash, Nium, Afterpay, Zip, Tonik Bank, TymeBank, Judo Bank, Revolut, Wise, Airwallex, Xendit, Ascend Money, Kredivo Holdings, KreditBee, HashKey Group, and MioTech.

Competition is supported by growing demand for digital payments, cross-border transactions, embedded finance, lending, insurance, and wealth management. Companies are also expanding through partnerships, acquisitions, local licensing, and new product offerings. Understanding country-specific regulations and customer preferences remains important because fintech operating requirements differ significantly across Asia-Pacific markets.

View Global Report on Fintech Market: https://www.mordorintelligence.com/industry-reports/global-fintech-market?utm_source=abnewswire

Market Outlook

The Asia-Pacific Fintech Market is expected to maintain strong growth as real-time payments, digital identity, mobile applications, embedded finance, and neobanking become increasingly integrated into financial services. Demand from consumers and businesses is creating opportunities across payments, lending, investments, insurance, and digital banking.

The Asia-Pacific Fintech Market Share and competitive positioning will continue to be influenced by local regulations, cybersecurity requirements, payment infrastructure, and customer adoption. Fintech providers that combine scalable digital platforms with strong compliance capabilities and locally relevant services are positioned to benefit from the region's expanding digital financial ecosystem.

For more insights on this market, please visit the Mordor Intelligence page: https://www.mordorintelligence.com/industry-reports/asia-pacific-fintech-market?utm_source=abnewswire

About Mordor Intelligence

Mordor Intelligence is a global market intelligence firm, founded in 2014, helping businesses make informed decisions through data-driven insights, industry expertise, and advanced analytics. With 550+ domain experts and on-ground specialists across 150+ countries, the company delivers comprehensive intelligence across aerospace & defense, agriculture, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, and logistics.

Its offerings include syndicated industry reports, custom research and advisory, and subscription platforms such as Synapse, Data Center Intelligence, and Robotics Intelligence. Mordor Intelligence is ISO 9001:2015 and ISO/IEC 27001:2022 certified, a member of ESOMAR and the Market Research Society of India, and a four-time Great Place to Work® honoree. Learn more at mordorintelligence.com.

For any inquiries or to access the full report, please contact:      

media@mordorintelligence.com   

https://www.mordorintelligence.com   

Media Contact
Company Name: Mordor Intelligence
Contact Person: Jignesh Thakkar
Email:Send Email
Phone: +1 617-765-2493
Address:11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli media@mordorintelligence.com
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

Charm City Inspections Ranked Number 1 in a Published Editorial Guide to Baltimore City Rental Inspection Services

Charm City Inspections Ranked Number 1 in a Published Editorial Guide to Baltimore City Rental Inspection Services

Published editorial feature recognizes Charm City Inspections for its Baltimore City rental inspection services, alongside lead and property inspection capabilities.

BALTIMORE, MD, October 31, 2026

Charm City Inspections has been ranked number one in a recently published editorial feature on Big News Network titled “Best Baltimore City Rental Inspection Services - Charm City Inspections Ranked Number 1”, which reviews Baltimore-area inspection providers based on rental inspection coverage, local requirements, reporting, scheduling, and related inspection services.

Charm City Inspections provides Baltimore City and Baltimore County rental inspections, along with lead inspections and property inspection services. The company states that its Baltimore City rental inspection process addresses requirements associated with minimum housing standards and the 2015 International Property Maintenance Code. Services can include documentation of property violations, rental inspection checklists, Certificates of Compliance, and other inspection records.

The company lists Maryland Home Inspector License #33696 and MDE Lead Paint Contractors License #17986. It also offers digital lead certificates, upfront pricing, clear inspection reports, and next-business-day service subject to availability. These services are intended for property owners, landlords, property managers, and real estate investors managing rental properties in the Baltimore area.

“This recognition reflects the continued demand for rental inspection services that understand Baltimore City requirements and provide clear documentation”, said a representative of Charm City Inspections. “Our focus is on helping property owners complete the inspection process with the appropriate records while also addressing related lead and property inspection needs.”

Baltimore rental property owners continue to navigate licensing, property maintenance, and lead-related requirements that can vary according to property characteristics and applicable regulations. Demand for inspection services also extends beyond rental licensing, with property owners increasingly seeking related lead and property assessments through local inspection providers.

The published editorial notes that selecting an inspection provider can involve factors including local experience, inspection scope, qualifications, reporting, scheduling availability, and follow-up documentation. Charm City Inspections' combination of rental, lead, and property inspection services was highlighted within the article's assessment.

Property owners can learn more about Charm City Inspections and its inspection services by visiting the company's website.

About Charm City Inspections

Charm City Inspections provides rental, lead, and property inspection services in Baltimore City and Baltimore County, Maryland. The company serves property owners, landlords, property managers, and real estate investors and lists Maryland Home Inspector License #33696 and MDE Lead Paint Contractors License #17986.

Media Contact
Company Name: Charm City Inspections
Contact Person: Danny Batkhan
Email:Send Email
Address:3235 Eastern Ave, Baltimore, MD 21224
City: Baltimore
State: Maryland (MD)
Country: United States
Website: https://charmcityinspections.com/

Charlotte Conway Announces A Thousand Small Goodbyes

A memoir of marriage, caregiving, and the everyday moments that kept a family connected

United States - October 31, 2026 - Charlotte Conway announces A Thousand Small Goodbyes: The Grace of Loving Through the Heartbreak of Alzheimer’s, a personal memoir about her husband, Robert Lee “Bob” Conway, their more than fifty years of marriage, and the family’s experience of his illness. The book follows their lives from the early uncertainties of misplaced belongings and repeated questions through the demands of daily care, his death, and the years of remembering him. Throughout, Conway keeps returning to the man she loved and the life they built together.

The story begins with a missing set of keys. Bob searches the familiar places, checking his pockets and retracing his steps, until Charlotte finds them beside the milk in the refrigerator. It is easy, at first, to laugh and move on. But other moments follow: glasses that cannot be found, questions asked again within minutes, sentences left unfinished. Conway describes the explanations a family reaches for when acknowledging a pattern would mean admitting something frightening. Her account gives that uncertainty room to be understood.

Before describing what changed, Conway introduces readers to Bob as he had always been. Born in 1932, the sixth of nine children, he grew up largely in Tulsa, Oklahoma, worked from an early age, served in the Army, and pursued his education with the help of the G.I. Bill. He loved language, literature, and the satisfaction of a carefully completed crossword. He could recite poetry from memory. He also loved his ukulele, golf with his sons, and a joke told well enough to be told again.

Their courtship began at Union College. Charlotte was playing French horn in the marching band when she fell face-first into mud, got up, and kept playing. Bob, covering the event for the student newspaper, noticed her determination. They married on August 24, 1958. Their shared life included teaching assignments in the United States, three years in Tanzania, and time in Beirut, Lebanon. They raised four children. Those years of work, travel, music, and family give readers a sense of the marriage that Alzheimer’s would ask them to carry differently.

The medical appointment came in December 2002, after concerns had become too persistent to explain away. Conway recalls the testing, the diagnosis of early, progressive dementia, and the adjustments that followed. Familiar activities continued for a time, but the family gradually had to reconsider driving, walking alone, dressing, and the many small decisions that had once required no thought. Each change involved more than practical arrangements. It meant finding a way to help Bob while respecting the independence and dignity that still mattered to him.

Conway writes candidly about becoming a caregiver while remaining a wife. Her daughter-in-law Tammie cared for Bob during the day, while Charlotte took evenings and weekends. Together, they arranged routines, shared responsibilities, and stayed alert through difficult nights. The memoir acknowledges exhaustion, frustration, private tears, and the guilt that can accompany a need for rest. “I had become a caregiver in every sense of the word, but I never stopped being a wife,” Conway writes. Even the simplest tasks carried the history of their marriage.

Music gave the family ways to reach Bob when conversation became difficult. Conway remembers listening to his favorite songs with him at two in the morning, singing hymns together, and watching him stand beside the piano as family members played. There were moments of humor, too, including his amusement at discovering that he had dressed in two different brown shoes. These memories sit beside the harder experiences without making them smaller. They show how a difficult day could still contain a laugh, a familiar tune, or a moment of closeness worth keeping.

The grandchildren knew him as Pops, and their presence brought another kind of connection. They listened to stories even when details wandered between different decades. They played, sang, and sat beside him. In one scene, Caleb asks his grandfather to read a picture book, then begins reading aloud himself when the words prove difficult for Bob. They turn the pages together. Conway pays attention to such exchanges because they preserve something easily missed in an account of decline: the relationship continuing, even when the ways of expressing it have changed.

The later chapters address physical decline, the family’s efforts to keep Bob comfortable, and the final goodbye. Conway also writes about the silence afterward, when a chair, a pair of reading glasses, or a half-finished crossword carries the weight of an absence. Bob died on October 2, 2012. His children, grandchildren, relatives, and friends contribute memories that widen the portrait beyond Charlotte’s own experience. Their recollections describe his generosity, his willingness to help, his love of music, and the ordinary pleasures they would most like to share with him again.

The book also shows readers outside a caregiving family what daily life can require. Its details make the work visible: the clothes arranged each morning, the bell beside the bed, the patient answer offered again after a sleepless night. Such tasks can be hard to describe in a short conversation. Her account explains why those daily responsibilities could be so difficult to put aside.

Faith is part of the family’s daily life throughout the memoir. Prayer, church, familiar hymns, and the presence of others helped Conway continue through nights when she had no easy answers. She also describes learning to accept practical help and to recognize her own limits. Readers caring for a spouse or parent may recognize the pressure to remain patient while feeling depleted. Friends and relatives may find a clearer understanding of why sitting with someone, sharing a task, or allowing a caregiver time to rest can matter so much.

Alongside the family’s story, the book includes a chapter reflecting on Alzheimer’s research and a directory of foundations and associations. Conway’s interest in what may become possible for other families grows out of what she and Bob experienced. Her central concern, however, remains personal: that a diagnosis should never be allowed to stand in for an entire life. As she writes, “Keep the story whole. That is the best thing I know how to tell you.” A Thousand Small Goodbyes follows that conviction by remembering Bob through the people, places, work, and love that made him who he was.

Find “A Thousand Small Good-byes: The Grace of Loving Through the Heartbreak of Alzheimer’s By Charlotte J. Conway”on Amazon: https://a.co/d/0cCVU8bw

About the Author

Charlotte Conway is the author of A Thousand Small Goodbyes. She and her husband, Bob, raised four children and shared a life that included teaching, travel, music, and family. Her memoir draws on their marriage and her experience caring for him alongside their family during his years with Alzheimer’s.

Media Contact

For book information, interview inquiries, and review copy requests, contact:

Charlotte Conway

Email: cconway371@gmail.com

Phone: 301-512-5834

Media Contact
Company Name: Charlotte Conway
Contact Person: Charlotte Conway
Email:Send Email
Phone: 301-512-5834
Country: United States
Website: a.co/d/0cCVU8bw

Ideavo Makes Full-Stack AI App Builder Free Forever, Eliminating Credit Markups

Bangalore, Karnataka, India - October 31, 2026 - Ideavo announced today that its AI-powered full-stack application builder is now available completely free. The move gives startup founders, independent software engineers, product managers, digital agencies, and non-technical creators full access to production-grade software creation tools without platform subscription fees or credit limits.

Rather than reselling artificial intelligence access through marked-up platform credits, Ideavo separates software creation tools from model computation costs. Users connect their existing API keys or accounts from providers such as OpenAI, Anthropic, Google, OpenRouter, OpenCode, Kimi, and others. Builders pay their chosen AI providers directly at direct rates, eliminating hidden platform surcharges.

The decision directly addresses a growing friction point across the software industry. Many creators already pay monthly subscriptions or direct API bills to major foundation model companies. Traditional AI development platforms like Lovable, Replit, Base44, and Emergent typically bundle access into proprietary credit pools, reselling compute at higher rates. When users exhaust these allowances, development halts until they buy expensive top-up packages.

Ideavo removes this bottleneck entirely. Large AI providers subsidize model execution at a scale that independent software products cannot match. Rather than offering short-term promotional credits or masking costs inside expensive pricing tiers, Ideavo provides a free development environment where users select the exact models that match their performance requirements and budget.

“AI app builders often charge customers a second time for intelligence they may already be paying for. We decided to take a different path,” said Siddhant Choudhary, founder of Ideavo and a former Microsoft engineer. “Ideavo provides the environment for turning ideas into real software, while builders remain free to choose their preferred AI provider, subscription, and cost structure. The platform gives more people the freedom to build websites or mobile apps without worrying about platform credits running out, because it’s free.”

On Ideavo, builders can launch unlimited projects and access every platform feature without paywalls. The system includes community support alongside full bring-your-own-key and direct subscription connectivity. Users can switch between free and paid AI models at will, avoiding single-vendor lock-in.

The platform turns natural language descriptions into complete applications. Users can create websites, mobile applications, full-stack web applications, internal operational tools, interactive dashboards, games, SaaS products, automated workflows, and minimum viable products (MVPs).

Ideavo handles the entire technical stack. It writes interface code, configures backend logic, establishes databases, integrates user authentication, sets up payment systems, and connects third-party APIs. Users can design visually, edit components directly, import existing codebases, export work directly to GitHub repositories, and deploy finished software to production. Builders maintain total ownership and control of their source code, preventing platform capture.

The company has expanded rapidly ahead of this pricing transition. Ideavo currently serves more than 100,000 active users and generates $2 million in annual recurring revenue, supported by a lean core team of 10 people.

By removing subscription barriers, Ideavo aims to make software production accessible to early-stage teams and individual builders who need long-term economic transparency. Software teams can now iterate, test, and deploy applications without artificial usage caps or recurring software seat charges.

Builders can start creating applications at https://ideavo.ai.

About Ideavo

Ideavo is a free AI-powered full-stack application builder founded by former Microsoft engineer Siddhant Choudhary. The platform allows founders, developers, agencies, and non-technical creators to turn plain-English descriptions into production-ready web applications, mobile apps, internal tools, and games. With a focus on developer autonomy, Ideavo offers unmetered project creation, complete source-code ownership, direct GitHub synchronization, and a bring-your-own-model infrastructure that eliminates AI credit markups.

Media Contact
Company Name: Ideavo
Contact Person: Siddhant Choudhary
Email:Send Email
City: Bangalore
State: Karnataka
Country: India
Website: ideavo.ai

TAX AI Lets South Korean Property Owners Check Estimated Refunds on Past Property Taxes and Simulate Future Tax Bills in One Place

Winner of South Korea's Minister of Land, Infrastructure and Transport Award holds a related patent and supplies its solution to major financial institutions and public agencies.

Busan, South Korea - October 31, 2026 - TAX AI, operated by South Korean tax-tech startup NEWEYE Corporation, uses an AI algorithm to handle frequently changing asset and real estate tax laws and complex special provisions. It simulates estimated refunds on real estate taxes customers have already paid and the amounts due at different points in time for taxes they will owe, helping customers check and manage their asset taxes on their own.

In South Korea, taxes on the same home can differ depending on when it is sold, how long it has been held, how many homes the owner has and whether the owner lived in it. Because tax law changes often and special provisions have strict requirements, taxpayers sometimes miss conditions for exemptions, deductions or reductions. TAX AI was built to solve this problem. Users see simulation results in real time by entering basic information, with no complicated paperwork.

Checking for refunds on the past five years of property taxes before filing for correction

Overpaid tax can be reclaimed by filing a request for correction within five years of the statutory filing deadline.

TAX AI's Real Estate Estimated Refund Simulation shows whether capital gains, comprehensive real estate holding and acquisition taxes paid in the past five years were overpaid or paid in error, and estimates the refund. Results appear in real time after users sign up and complete quick identity verification.

The highest estimated real estate refund retrieved on TAX AI to date is KRW 188 million. (This is the amount actually refunded through an independent tax accountant on July 15, 2026, based on the estimated refund retrieved on TAX AI on May 25, 2026.)

Note: Results on TAX AI are estimates. Actual tax amounts and refund eligibility may vary depending on each user's filing and payment history.

TAX AI only provides estimated refund lookups and does not offer tax representation. When a customer requests representation, a qualified tax accountant handles it independently.

Simulations by tax type to calculate real estate taxes in advance

With simulations for each tax type, users can calculate real estate taxes in advance, including capital gains, holding, acquisition, inheritance and gift taxes. For example, a homeowner planning to sell can enter basic information into TAX AI's Simplified Capital Gains Tax Simulation to see the estimated tax. An AI algorithm matches the information to one of 9.3 million cases under Korean tax law, checks exceptions, reductions and surcharges, and presents the legal basis. No documents or tax office visits are needed.

Simplified capital gains and holding tax simulations reflecting South Korea's 2026 tax reform proposal compare estimated taxes over the next 10 years side by side. TAX AI also offers inheritance and gift tax simulations, simplified valuation of unlisted shares, and employee tax calculations for severance pay, retirement pension (defined benefit/defined contribution) and individual retirement pension (IRP) payouts, and the monthly rent deduction in year-end tax settlement. It has tracked daily changes in tax law since 2020 and applies the latest rules. By showing taxes already paid and taxes to come in one place, TAX AI helps users review and prepare for taxes on the real estate they own.

Patent, government recognition, ISO certifications and public and financial sector clients

TAX AI raised the profile of its in-house AI algorithm by winning the sole grand prize, the Minister's Award, at the Ministry of Land, Infrastructure and Transport's 2024 Real Estate Service Industry Startup Competition. It later registered a patent (Korean Patent No. 10-2907828) for technology that simulates real estate taxes and compares tax reduction benefits. Its ISO/IEC 27001, ISO/IEC 27701 and ISO 9001 certifications reflect its focus on information security, privacy and quality management. TAX AI currently supplies its service to major financial institutions and public agencies, including the Korea Real Estate Board, KB Real Estate, Woori Bank, Hana Card and BNK Busan Bank, and is expanding across finance and real estate, including through a three-party agreement with Samsung C&T and KB Kookmin Bank.

For more details, visit:

TAX AI Real Estate Estimated Refund Simulation: https://back.taxai.kr/

TAX AI website: https://taxai.kr

About TAX AI

TAX AI is an asset and real estate tax service operated by NEWEYE Corporation, a tax-tech startup based in Busan, South Korea. It simulates estimated refunds on real estate taxes users have already paid and the taxes they will owe in the future.

More information is available at https://taxai.kr.

 

Media Contact
Company Name: NEWEYE
Contact Person: Soobin Park
Email:Send Email
City: Busan
Country: South Korea
Website: taxai.kr

Peripheral T-Cell Lymphoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

The Peripheral T-Cell Lymphoma Clinical Trial analysis report delivers important insights into ongoing research on 30+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

(Albany, US) On October 30, 2026, DelveInsight’s “Peripheral T-Cell Lymphoma Pipeline Insights 2026” report provides comprehensive insights about 30+ companies and 32+ pipeline drugs in the Peripheral T-Cell Lymphoma pipeline landscape. It covers the Peripheral T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peripheral T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Peripheral T-Cell Lymphoma Pipeline @ https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphomas-ptcl-pipeline-insight

Key Takeaways from the Peripheral T-Cell Lymphoma Pipeline Report

• On October 28, 2026, National Cancer Centre Singapore updated its POLAR clinical trial evaluating pembrolizumab in combination with olaparib in patients with relapsed or refractory Peripheral T-Cell Lymphoma. The study aims to investigate the efficacy and safety of this combination, with key endpoints including objective response rate, progression-free survival, overall survival, and treatment-related adverse events. The trial is exploring the potential of combining immune checkpoint inhibition with PARP inhibition to improve treatment outcomes in patients with difficult-to-treat PTCL.
• On October 13, 2026, Prescient Therapeutics Limited announced its September 2026 quarterly business update, highlighting the continued development of PTX-100 for T-cell lymphomas. The company reported that PTX-100 had completed its Phase Ib expansion cohort study, demonstrating encouraging efficacy and safety findings in patients with T-cell lymphoma. Prescient is evaluating further clinical development opportunities in Peripheral T-Cell Lymphoma (PTCL), with additional studies expected to be considered following selection of the recommended Phase II dose in its ongoing cutaneous T-cell lymphoma program. PTX-100 is an investigational geranylgeranyl transferase type I (GGT-I) inhibitor designed to interfere with cancer-related signaling pathways.
• On October 15, 2026, Yale University updated its Phase II clinical study evaluating pembrolizumab in combination with brentuximab vedotin in patients with relapsed or refractory CD30-positive T-cell lymphoma, including Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. The open-label, multicenter study aims to enroll approximately 43 patients and assess the antitumor activity of the combination, with an objective response rate of approximately 65% as the anticipated outcome. The study will also evaluate treatment safety, tolerability, and response durability.
• DelveInsight’s Peripheral T-Cell Lymphoma pipeline report depicts a robust space with 30+ active players working to develop 32+ pipeline therapies for Peripheral T-Cell Lymphoma treatment.
• The leading Peripheral T-Cell Lymphoma Companies include Corvus Pharmaceuticals, Dizal Pharmaceuticals, Innate Pharma, Secura Bio, Shanghai YingLi Pharmaceutical, Prescient Therapeutics, CellCentric, BioInvent International, HUYABIO International, Pfizer, Kyowa Kirin, Takeda Pharmaceutical, Daiichi Sankyo, Citius Pharmaceuticals, Acrotech Biopharma, Sobi and others.
• Promising Peripheral T-Cell Lymphoma Pipeline Therapies such as XNW5004, BR101801, FG-M131, KK2223 and others.

Stay ahead with the most recent Peripheral T-Cell Lymphoma pipeline outlook with DelveInsight @ Peripheral T-Cell Lymphoma Treatment Drugs

The Peripheral T-Cell Lymphoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Peripheral T-Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to the Peripheral T-Cell Lymphoma.

Peripheral T-Cell Lymphoma Overview

Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of aggressive non-Hodgkin lymphomas arising from mature, post-thymic T cells or, in some entities, natural killer (NK) cells. More than 30 distinct entities are recognized across nodal, extranodal, leukemic and cutaneous categories, including PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic/T-follicular helper (TFH) lymphomas and anaplastic large-cell lymphoma (ALCL). PTCLs generally have an aggressive clinical course and are frequently diagnosed at an advanced stage. They account for approximately 10–15% of non-Hodgkin lymphomas, although their incidence varies geographically.

Peripheral T-Cell Lymphoma Emerging Drugs Profile

• XNW5004: Evopoint Biosciences

XNW5004 is an investigational, orally administered selective EZH2 inhibitor developed by Evopoint Biosciences, designed to inhibit both wild-type and mutant EZH2 and suppress H3K27 trimethylation, thereby promoting cell-cycle arrest and apoptosis in tumor cells. In September 2024, it received Breakthrough Therapy Designation (BTD) from China’s CDE for relapsed/refractory (R/R) PTCL based on clinical data demonstrating promising activity. In a Phase I/II study, XNW5004 achieved an ORR of 70.3% in PTCL at the 1,200 mg BID dose, with median PFS of 15.7 months and median duration of response of 13.9 months. Currently, the drug is in Phase III study evaluating XNW5004 versus chidamide in R/R PTCL.

• BR101801: Boryung Pharmaceutical

BR101801 (bosmolisib) is an oral, investigational triple inhibitor of PI3K-?, PI3K-? and DNA-PK being developed by Boryung Pharmaceutical for relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). By simultaneously inhibiting PI3K signaling and DNA-PK, the drug is designed to suppress tumor-cell growth, induce cell-cycle arrest and apoptosis, and reduce the stability of oncogenic c-Myc. In an earlier Phase I study, BR101801 demonstrated an ORR of 31.6% and a complete response rate of 21.1% in evaluable R/R PTCL patients, supporting further development. The Phase II study is designed to evaluate BR101801 monotherapy in patients with R/R PTCL with 200 mg once daily being the established recommended Phase II dose.

• FG-M131: FutureGen Biopharmaceutical

FG-M131 is an investigational antibody–drug conjugate (ADC) targeting T-cell receptor beta constant region 1 (TRBC1), a component of the ?? T-cell receptor complex. By selectively targeting TRBC1-positive malignant T cells while potentially sparing TRBC2-positive normal T cells, it represents a novel targeted approach for T-cell malignancies. The drug is being evaluated in a multicenter, open-label Phase I/II study in patients with TRBC1-positive relapsed/refractory PTCL, assessing safety, pharmacokinetics and preliminary antitumor activity.

• KK2223: Kyowa Kirin

KK2223 is an investigational, first-in-class therapeutic developed by Kyowa Kirin for T-cell non-Hodgkin lymphomas, including relapsed/refractory PTCL and CTCL. It is being evaluated in a first-in-human, Phase I, open-label, multicenter study, evaluating intravenous KK2223 through dose-escalation and backfill cohorts. The trial is designed to assess safety, tolerability, pharmacokinetics and pharmacodynamics in patients with relapsed/refractory PTCL or CTCL. The study includes PTCL subtypes such as PTCL-NOS, nodal TFH lymphoma and ALCL, positioning KK2223 as an emerging investigational option for heavily pretreated T-cell malignancies.

The Peripheral T-Cell Lymphoma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Peripheral T-Cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peripheral T-Cell Lymphoma Treatment.
• Peripheral T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Peripheral T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peripheral T-Cell Lymphoma market

Explore groundbreaking therapies and clinical trials in the Peripheral T-Cell Lymphoma Pipeline @ New Peripheral T-Cell Lymphoma Drugs

Peripheral T-Cell Lymphoma Companies

Corvus Pharmaceuticals, Dizal Pharmaceuticals, Innate Pharma, Secura Bio, Shanghai YingLi Pharmaceutical, Prescient Therapeutics, CellCentric, BioInvent International, HUYABIO International, Pfizer, Kyowa Kirin, Takeda Pharmaceutical, Daiichi Sankyo, Citius Pharmaceuticals, Acrotech Biopharma, Sobi and others.

Peripheral T-Cell Lymphoma Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Peripheral T-Cell Lymphoma Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Peripheral T-Cell Lymphoma Market Drivers and Barriers

Scope of the Peripheral T-Cell Lymphoma Pipeline Report

• Coverage- Global
• Peripheral T-Cell Lymphoma Companies- Corvus Pharmaceuticals, Dizal Pharmaceuticals, Innate Pharma, Secura Bio, Shanghai YingLi Pharmaceutical, Prescient Therapeutics, CellCentric, BioInvent International, HUYABIO International, Pfizer, Kyowa Kirin, Takeda Pharmaceutical, Daiichi Sankyo, Citius Pharmaceuticals, Acrotech Biopharma, Sobi and others.
• Peripheral T-Cell Lymphoma Pipeline Therapies- XNW5004, BR101801, FG-M131, KK2223 and others.
• Peripheral T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Peripheral T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Peripheral T-Cell Lymphoma Therapies and clinical trials @ Peripheral T-Cell Lymphoma Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Peripheral T-Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Peripheral T-Cell Lymphoma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Peripheral T-Cell Lymphoma Collaboration Deals
9. Late Stage Products (Pre-registration)
10. XNW5004: Evopoint Biosciences
11. Late Stage Products (Phase III)
12. Mid Stage Products (Phase II)
13. BR101801: Boryung Pharmaceutical
14. Comparative Analysis
15. Early Stage Products (Phase I/II)
16. KK2223: Tr1X Inc.
17. Comparative Analysis
18. Peripheral T-Cell Lymphoma Key Companies
19. Peripheral T-Cell Lymphoma Key Products
20. Peripheral T-Cell Lymphoma Unmet Needs
21. Peripheral T-Cell Lymphoma Market Drivers and Barriers
22. Peripheral T-Cell Lymphoma Future Perspectives and Conclusion
23. Peripheral T-Cell Lymphoma Analyst Views
24. Peripheral T-Cell Lymphoma Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: Ukraine
Website: https://www.delveinsight.com/report-store/peripheral-t-cell-lymphomas-ptcl-pipeline-insight

Prader Willi Syndrome Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

The Prader-Willi Syndrome Clinical Trial analysis report delivers important insights into ongoing research on 20+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

(Albany, US) On October 30, 2026, DelveInsight’s “Prader Willi Syndrome Pipeline Insights 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Prader Willi Syndrome pipeline landscape. It covers the Prader-Willi Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Prader Willi Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Prader Willi Syndrome Pipeline @ https://www.delveinsight.com/sample-request/prader-willi-syndrome-pipeline-insight

Key Takeaways from the Prader Willi Syndrome Pipeline Report

• On October 23, 2026- Aardvark Therapeutics reported exploratory clinical data from its terminated Phase III HERO trial and open-label extension study evaluating ARD-101 for hyperphagia associated with Prader-Willi Syndrome. The company reported that hyperphagia questionnaire scores declined by Week 2 during dose escalation with ARD-101 but returned toward baseline within two weeks after treatment discontinuation. The HERO trial was terminated early after 67 of the planned 90 participants had been randomized, and the company emphasized that all efficacy findings should be considered exploratory rather than confirmatory. These findings will help guide the company's future clinical development strategy for ARD-101, an investigational gut-restricted small-molecule taste receptor agonist designed to stimulate satiety-related gut hormones, including GLP-1 and cholecystokinin.
• In September, 2026 – Neurocrine Biosciences announced research presentations at the Foundation for Prader-Willi Research 2026 Annual Research Symposium, covering the PWS-VISTA and BRAVE-PWS observational studies. These studies are designed to generate real-world evidence on VYKAT XR (diazoxide choline extended-release tablets), including long-term treatment outcomes, safety, and caregiver experiences in people living with PWS.
• DelveInsight’s Prader Willi Syndrome pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Prader Willi Syndrome treatment.
• The leading Prader Willi Syndrome Companies such as Aardvark Therapeutics, Inc., Neurocrine Biosciences Inc., Soleno Therapeutics Inc., Harmony Biosciences Holdings Inc. and others.
• Promising Prader Willi Syndrome Pipeline Therapies such as Pitolisant, BMB-101, RM718, CCT987, and others.

Stay ahead with the most recent Prader Willi Syndrome pipeline outlook with DelveInsight @ Prader Willi Syndrome Treatment Drugs

The Prader Willi Syndrome Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Prader Willi Syndrome Pipeline Report also highlights the unmet needs with respect to the Prader Willi Syndrome.

Prader Willi Syndrome Overview

Prader-Willi syndrome (PWS) is a rare, complex genetic disorder affecting the metabolic, endocrine, and neurological systems. It is characterized by severe hypotonia and feeding difficulties during infancy, followed by developmental delay, hyperphagia (excessive eating), impaired satiety, and progressive obesity. Hypothalamic dysfunction also contributes to endocrine abnormalities such as growth hormone deficiency, hypogonadism, hypothyroidism, and, less commonly, central adrenal insufficiency. PWS results from the absence of expression of paternally inherited genes in the chromosome 15q11.2–q13 region. Approximately 70% of cases are associated with a paternal deletion, around 25% with maternal uniparental disomy (both chromosome 15 copies inherited from the mother), and a smaller proportion with defects in the genomic imprinting center. The loss of paternally expressed genes disrupts normal hypothalamic function, leading to impaired regulation of appetite, energy expenditure, and multiple endocrine pathways. This produces the characteristic progression from neonatal hypotonia and poor feeding to hyperphagia, impaired satiety, and severe obesity. Abnormal neuropeptide signaling, including alterations in the oxytocin and ghrelin systems, contributes to hyperphagia, while hypothalamic dysfunction can cause growth hormone deficiency, hypogonadism, hypothyroidism, and central adrenal insufficiency.

Prader Willi Syndrome Emerging Drugs Profile

• Pitolisant: Harmony Biosciences

Pitolisant is a high-affinity inverse agonist at the H3 receptor, which normally inhibits histamine synthesis and release. By preventing endogenous histamine from binding to these receptors, pitolisant increases histaminergic activity in the central nervous system, thereby enhancing wakefulness. It also modulates the release of other neurotransmitters, contributing to its stimulating effects without the higher abuse potential associated with traditional stimulants like amphetamines. The drug has received Orphan Drug Designation from the FDA and is currently in Phase III stage of its development for the treatment of Prader-Willi syndrome.

• BMB-101: Bright Minds Biosciences

BMB-101 is an investigational, novel scaffold 5-HT?C receptor Gq-protein-biased agonist being evaluated for Prader-Willi syndrome (PWS), particularly to address hyperphagia and associated behavioral symptoms. It selectively activates the 5-HT?C receptor through the Gq-protein signaling pathway while minimizing ?-arrestin recruitment, which is intended to reduce receptor desensitization and tolerance during chronic treatment. In PWS, genetic alterations can result in reduced 5-HT?C receptor function, providing a rationale for enhancing 5-HT?C signaling. By stimulating 5-HT?C-mediated signaling, BMB-101 is intended to modulate appetite and behavioral pathways and potentially reduce hyperphagia and related behavioral abnormalities in Prader-Willi Syndrome. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Prader-Willi Syndrome.

• RM 718: Rhythm Pharmaceuticals

RM-718 is an investigational synthetic cyclic heptamer peptide and selective melanocortin-4 receptor (MC4R) agonist being evaluated for Prader-Willi syndrome (PWS), including its severe hyperphagia and obesity. It is formulated as a sustained-release, once-weekly subcutaneous injection. RM-718 acts by selectively activating MC4R, a key receptor in the hypothalamic melanocortin pathway that regulates appetite, energy expenditure, and body weight. By stimulating MC4R signaling, RM-718 is intended to enhance satiety, reduce excessive food intake (hyperphagia), and potentially improve energy balance and obesity associated with PWS. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Prader-Willi Syndrome.

• CCT 987: Canary Cure Therapeutics

CCT-987 is a first-in-class, dual-action RNA therapeutic being developed for Prader-Willi syndrome (PWS). The drug is designed to directly correct peripheral adipose biology by delivering a payload of CB1R siRNA and leptin mRNA directly to subcutaneous adipose tissue. The dual RNA therapy is intended to clear the CB1R molecular blockade and deliver a physiological pulse of leptin, thereby re-engaging the hypothalamic satiety circuit and promoting fat loss while enhancing lean muscle mass. Currently, the drug is being evaluated in the Preclinical stage of its development for the treatment of Prader-Willi Syndrome.

The Prader Willi Syndrome Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Prader Willi Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prader Willi Syndrome Treatment.
• Prader Willi Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Prader Willi Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Prader Willi Syndrome market

Explore groundbreaking therapies and clinical trials in the Prader Willi Syndrome Pipeline @ New Prader Willi Syndrome Drugs

Prader Willi Syndrome Companies

Aardvark Therapeutics, Inc., Neurocrine Biosciences Inc., Soleno Therapeutics Inc., Harmony Biosciences Holdings Inc. and others.

Prader Willi Syndrome Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Prader Willi Syndrome Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Prader Willi Syndrome Market Drivers and Barriers

Scope of the Prader Willi Syndrome Pipeline Report

• Coverage- Global
• Prader Willi Syndrome Companies- Aardvark Therapeutics, Inc., Neurocrine Biosciences Inc., Soleno Therapeutics Inc., Harmony Biosciences Holdings Inc. and others.
• Prader Willi Syndrome Pipeline Therapies- Pitolisant, BMB-101, RM718, CCT987, and others.
• Prader Willi Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Prader Willi Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Prader Willi Syndrome Therapies and clinical trials @ Prader Willi Syndrome Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Prader Willi Syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Prader Willi Syndrome – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Prader Willi Syndrome Collaboration Deals
9. Late Stage Products (Pre-registration)
10. Pitolisant: Harmony Biosciences
11. Late Stage Products (Phase III)
12. Mid Stage Products (Phase II)
13. BMB-101: Bright Minds Biosciences
14. Comparative Analysis
15. Early Stage Products (Phase I/II)
16. RM 718: Rhythm Pharmaceuticals
17. Comparative Analysis
18. Prader Willi Syndrome Key Companies
19. Prader Willi Syndrome Key Products
20. Prader Willi Syndrome Unmet Needs
21. Prader Willi Syndrome Market Drivers and Barriers
22. Prader Willi Syndrome Future Perspectives and Conclusion
23. Prader Willi Syndrome Analyst Views
24. Prader Willi Syndrome Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/prader-willi-syndrome-pipeline-insight

Biliary Tumor Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

The Biliary Tumor Clinical Trial analysis report delivers important insights into ongoing research on 50+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

(Albany, US) On October 31, 2026, DelveInsight’s “Biliary Tumor Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Biliary Tumor pipeline landscape. It covers the Biliary Tumor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Biliary Tumor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Biliary Tumor Pipeline @ https://www.delveinsight.com/sample-request/biliary-tumor-pipeline-insight

Key Takeaways from the Biliary Tumor Pipeline Report

• On October 25, 2026, Akeso Inc. announced positive overall survival results from its Phase III HARMONi-GI1 trial evaluating ivonescimab in combination with chemotherapy versus durvalumab plus chemotherapy as first-line treatment for patients with advanced biliary tract cancer. The study met its primary endpoint of overall survival, demonstrating a median overall survival of 14.9 months compared with 12.1 months in the control arm, representing a 25% reduction in the risk of death (HR: 0.75; p=0.0031). The trial also achieved key secondary endpoints, including progression-free survival and objective response rate. Median PFS was 8.4 months versus 5.8 months, while the objective response rate was 53.8% versus 32.5%. These findings highlight the potential of ivonescimab-based combination therapy as a new treatment approach for advanced biliary tract cancer.
• On October 21, 2026, Summit Therapeutics announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab in combination with chemotherapy for the first-line treatment of advanced biliary tract cancer. The registration-enabling Phase II/III EA2251 trial (NCT07765433) will compare ivonescimab plus gemcitabine and cisplatin against pembrolizumab or durvalumab combined with gemcitabine and cisplatin. The study is designed to assess the safety and efficacy of these treatment approaches, with overall survival as its primary endpoint. Clinical trial site activations in the United States are expected to begin in the fourth quarter of 2026.
• On October 12, 2026, Leads Biolabs announced that the US FDA granted Fast Track Designation to opamtistomig (LBL-024), an investigational PD-L1/4-1BB bispecific antibody, for the first-line treatment of patients with advanced or metastatic biliary tract cancer. The designation was supported by preliminary findings from an ongoing Phase II clinical study evaluating opamtistomig in combination with chemotherapy. The investigational therapy is designed to simultaneously inhibit PD-L1-mediated immune suppression and activate the 4-1BB costimulatory pathway, potentially enhancing antitumor immune responses. This regulatory milestone is expected to support the continued clinical development of opamtistomig for advanced biliary tract cancer.
• DelveInsight’s Biliary Tumor pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Biliary Tumor treatment.
• The leading Biliary Tumor Companies include Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceuticals, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited and others.
• Promising Biliary Tumor Pipeline Therapies such as Rilvegostomig, SHR-A1811, AMG193, and others.

Stay ahead with the most recent Biliary Tumor pipeline outlook with DelveInsight @ Biliary Tumor Treatment Drugs

The Biliary Tumor Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Biliary Tumor Pipeline Report also highlights the unmet needs with respect to the Biliary Tumor.

Biliary Tumor Overview

Biliary tumors, encompassing both benign and malignant growths, originate in the biliary system, which includes the bile ducts and gallbladder. These tumors can obstruct the flow of bile, leading to jaundice, itching, and potentially severe complications. Malignant biliary tumors, such as cholangiocarcinoma and gallbladder cancer, are often diagnosed at advanced stages due to their subtle and non-specific early symptoms, resulting in a poor prognosis. Risk factors include chronic biliary inflammation, primary sclerosing cholangitis, liver fluke infections, and certain genetic conditions. Diagnosis typically involves imaging studies, endoscopic techniques, and biopsy, while treatment options vary from surgical resection to palliative care, depending on the tumor type and stage.

Biliary Tumor Emerging Drugs Profile

• Rilvegostomig: AstraZeneca

Rilvegostomig (formerly AZD2936) is a bispecific antibody developed by AstraZeneca, targeting both PD-1 and TIGIT to enhance immune responses against cancer. Derived from Compugen's COM902 antibody, it aims to maximize the blockade of these pathways through cooperative binding, potentially improving therapeutic outcomes. Scheduled to progress into Phase III trials for indications like Biliary cancer, non-small cell lung cancer and gastric cancer, rilvegostomig is also being evaluated in combination with AstraZeneca's antibody-drug conjugates such as Enhertu, Dato-DXd, and AZD0901, as part of a strategy to leverage its differentiated bispecific format for greater efficacy.

• SHR-A1811: Jiangsu HengRui Medicine

SHR-A1811 is an antibody-drug conjugate (ADC) composed of trastuzumab, a cleavable linker, and a novel topoisomerase I inhibitor payload called SHR169265. It targets HER2-expressing tumor cells, delivering the cytotoxic payload upon internalization. Once inside the cell, the linker is cleaved, releasing SHR169265 which inhibits topoisomerase I, an essential enzyme for DNA replication and transcription, leading to cell cycle arrest and apoptosis. SHR-A1811 has shown promising antitumor activity in preclinical models and is currently being evaluated in multiple phase I-III clinical trials for HER2-positive and HER2-low breast cancer, gastric cancer, and other solid tumors. Currently, the drug is in Phase II stage of its clinical trial for the treatment of biliary cancer.

• AMG 193: Amgen

AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of solid tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of biliary cancer.

The Biliary Tumor Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Biliary Tumor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Biliary Tumor Treatment.
• Biliary Tumor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Biliary Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Biliary Tumor market

Explore groundbreaking therapies and clinical trials in the Biliary Tumor Pipeline @ New Biliary Tumor Drugs

Biliary Tumor Companies

Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceuticals, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited and others.

Biliary Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Biliary Tumor Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Biliary Tumor Market Drivers and Barriers

Scope of the Biliary Tumor Pipeline Report

• Coverage- Global
• Biliary Tumor Companies- Jazz Pharmaceuticals, TransThera Sciences, Chia Tai Tianqing Pharmaceuticals, Jiangsu HengRui Medicine, RemeGen, Shanghai Miracogen, ModeX Therapeutics, Intensity Therapeutics, GeneQuantum Healthcare, Elicio Therapeutics, SystImmune, Lanova Medicines Limited and others.
• Biliary Tumor Pipeline Therapies- Rilvegostomig, SHR-A1811, AMG193, and others.
• Biliary Tumor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Biliary Tumor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Biliary Tumor Therapies and clinical trials @ Biliary Tumor Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Biliary Tumor: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Biliary Tumor – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Biliary Tumor Collaboration Deals
9. Late Stage Products (Pre-registration)
10. Rilvegostomig: AstraZeneca
11. Late Stage Products (Phase III)
12. Mid Stage Products (Phase II)
13. SHR-A1811: Jiangsu HengRui Medicine
14. Comparative Analysis
15. Early Stage Products (Phase I/II)
16. AMG 193: Amgen
17. Comparative Analysis
18. Biliary Tumor Key Companies
19. Biliary Tumor Key Products
20. Biliary Tumor Unmet Needs
21. Biliary Tumor Market Drivers and Barriers
22. Biliary Tumor Future Perspectives and Conclusion
23. Biliary Tumor Analyst Views
24. Biliary Tumor Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/biliary-tumor-pipeline-insight

Eddie Barbash Returns to Chamber Music Rochester for an Afternoon of Gershwin and Jazz

Eddie Barbash Returns to Rochester, NY

Chamber Music Rochester continues its 50th Anniversary Season on Sunday, November 15, 2026, with Eddie Barbash from The Late Show Band, the Sequel.

ROCHESTER, NY – October 31, 2026 – Chamber Music Rochester continues its 50th Anniversary Season on Sunday, November 15, 2026, with Eddie Barbash of The Late Show Band, the Sequel. The concert begins at 3:00 p.m. at Beston Hall in Nazareth University’s Glazer Music Performance Center, 4245 East Avenue.

The program opens with George Gershwin’s Rhapsody in Blue, arranged for piano and string quintet. After intermission, saxophonist Eddie Barbash joins pianist and arranger Kyle Athayde for jazz standards and original arrangements featuring a jazz quartet and string quartet.

Barbash, a founding member of the house band for The Late Show with Stephen Colbert, returns to bring jazz and chamber music together on an intimate stage.

A free pre-concert talk begins at 2:30 p.m. and offers an approachable introduction to the program. No musical background is needed.

Single tickets are $35. Students and children attend for free by visiting the welcome table. To purchase tickets, visit chambermusicrochester.org/tickets.

For media inquiries or additional information, contact Meg Burton Tudman at contact@chambermusicrochester.org.

The concert is generously sponsored by Alison and John Currie.

About Chamber Music Rochester

Chamber Music Rochester presents five intimate concerts each season featuring local, professional musicians and acclaimed guests. Its performances, free pre-concert talks, and community outreach bring people closer to the music and to one another.

Media Contact
Company Name: Chamber Music Rochester
Contact Person: Meg Burton Tudman
Email:Send Email
Country: United States
Website: https://www.chambermusicrochester.org/

Lakeland Clinic Uses Shockwave Therapy to Treat Chronic Tendon and Joint Pain Without Surgery

A specialist administers a noninvasive shockwave therapy treatment at ChiroMed Wellness Centers in Lakeland, Florida, to relieve chronic knee and tendon pain without surgery.

ChiroMed Wellness Centers offers shockwave therapy at its Lakeland and The Villages offices, using the Omniwave acoustic wave system to treat chronic tendon, ligament, and joint pain such as plantar fasciitis and shoulder, hip and knee pain. Led by Dr. Justin Bergin, DC, the clinic starts every plan with an exam and tracks progress against baseline markers, giving active adults in Central Florida a noninvasive, drug-free option.

LAKELAND, Fla. - October 30, 2026 - ChiroMed Wellness Centers offers shockwave therapy in Florida at its Lakeland and The Villages offices for adults living with chronic tendon, ligament and joint pain. The clinic uses the Omniwave acoustic wave system, a noninvasive treatment that sends pressure pulses through the skin to increase local blood flow and support repair in tissue that has stopped healing on its own. Led by Dr. Justin Bergin, DC, the practice uses the treatment for conditions such as plantar fasciitis and shoulder, hip and knee pain, and every patient receives an exam before a plan is set.

Active Lifestyles and Lingering Tendon Pain in Central Florida

In Central Florida, staying active is a year-round habit. Golf, pickleball, and long walks fill many residents’ calendars, and many working adults spend full shifts on their feet. That activity takes a toll on tendons and joints over time. Heel pain from plantar fasciitis, a shoulder that flares after a round of golf, or a knee that aches on the stairs can linger for months.

By the time these patients reach a specialist, many have already tried the usual remedies. Rest, stretching, braces, and over-the-counter pain relievers may bring short-term relief, but chronic tendon problems often return once normal activity resumes. Tendons also tend to recover more slowly with age, which is why these injuries are common among adults over 40. Steroid injections and surgery remain options for some, yet many patients ask about approaches that do not involve medication, downtime, or an operating room.

How Shockwave Therapy Works

For patients considering shockwave therapy in Florida, the process is simple. A clinician places a handheld applicator over the painful area with a layer of gel. The device delivers acoustic pressure waves through the skin into the affected tendon, ligament, or joint tissue. The goal is to increase circulation and prompt a repair response in tissue caught in a cycle of irritation. Patients usually feel a firm tapping or pulsing sensation, and the intensity is adjusted to their comfort.

Research supports acoustic wave therapy for certain conditions. A 2024 systematic review and meta-analysis of randomized controlled trials found that extracorporeal shockwave therapy for tendon pain was associated with meaningful pain reduction across several tendinopathies, while noting that more research is needed to define the best protocol for each condition.

Benefits patients may experience include:

• Noninvasive care with no incisions, needles, or anesthesia

• A drug-free approach that may reduce reliance on pain medication

• Short sessions with little to no downtime

• Treatment aimed at the tendon, ligament, or joint tissue causing the pain

• Support for improved mobility in daily activities and recreation

• A structured course with progress tracked at a set review point

Who Is a Candidate for Shockwave Therapy

Shockwave therapy is not appropriate for everyone. The clinic does not use it for patients who are pregnant, take blood-thinning medications, or have an active infection or tumor in the treatment area, or for those who recently received a steroid injection at the site. Pain that originates from a nerve root or is referred from elsewhere in the body is also a poor fit, which is one reason the exam comes first. Temporary redness or soreness after a session is possible.

An Exam-First, Measured Approach

ChiroMed’s approach to shockwave therapy in Florida is built around evaluation and measurement. Dr. Bergin, who has practiced chiropractic care for 22 years, personally performs exams at both offices. Each plan begins with a hands-on evaluation and X-rays when needed, followed by a report of findings that explains whether shockwave therapy is appropriate and how many sessions are recommended. Progress is checked against baseline markers at a scheduled review. If a patient is not improving by then, the plan changes.

“Most of the people we see aren’t training for a marathon. They want to finish 18 holes, play pickleball with their friends, or get through a workday without their heel or shoulder running the show,” said Dr. Justin Bergin, DC, founder of ChiroMed Wellness Centers. “Shockwave gives us a way to work on tendon and joint problems that haven’t responded to rest and stretching without putting someone on medication or steering them toward surgery. We’re careful about who it’s for, and we tell patients up front when it isn’t the right fit.”

When appropriate, the clinic pairs shockwave sessions with other conservative care, including soft tissue therapy, knee decompression, and chiropractic adjustments. With offices in Lakeland and Lady Lake, the practice serves patients across Polk County, the Villages, and nearby communities.

“We built the program around numbers we can track,” Bergin said. “Before the first session, we know where a patient is starting from. At the review, we look at those same markers again. That keeps everyone honest, including us, and it means nobody spends weeks on a treatment that isn’t helping.”

Scheduling a Consultation in Lakeland and The Villages

ChiroMed Wellness Centers is accepting new patients at both locations. Adults who want to know whether they are candidates can schedule a consultation, which includes an exam and a review of findings. Shockwave therapy is generally self-pay, with payment plans available, while chiropractic services may be billed to insurance. Details about shockwave therapy in Florida and the consultation process are available on the clinic’s website, and patients can also call either office to book a visit.

About ChiroMed Wellness Centers

ChiroMed Wellness Centers is a chiropractic and integrative wellness practice with offices in Lakeland and Lady Lake, Florida. Founded by Dr. Justin Bergin, DC, the practice specializes in chiropractic care, spinal decompression, soft tissue therapy, and shockwave therapy for chronic musculoskeletal pain. ChiroMed Wellness Centers is committed to providing patients in Lakeland, The Villages, and surrounding areas with noninvasive, drug-free treatment options for back, joint and tendon conditions.

Media Contact
Company Name: Chiromed Wellness Centers
Contact Person: Dr. Justin Bergin
Email:Send Email
Phone: (863) 940-3444
Address:6595 Florida Ave S, Suite 13
City: Lakeland
State: FL
Country: United States
Website: https://chiromedfl.com/